

ASX ANNOUNCEMENT

31 May 2024

EZZ Secures Major Sales Agreement with Pinehills (Hong Kong) Limited

Highlights

- EZZ has signed a five-year sales agreement with Pinehills (Hong Kong) Limited.
- Pinehills has committed to purchasing EZZ-branded products with a minimum value of A\$15m in the first 12-months.
- Annual purchase volumes will increase by a minimum of 10% annually over the five-year agreement.
- The agreement will expand the distribution of EZZ's products into key markets including China, Vietnam and other markets within Southeast Asia.

EZZ Life Science Holdings Limited (ASX: EZZ) (EZZ or the Company), a genomic life science company with a mission to improve quality of life and human health, is pleased to announce it has entered into a major sales agreement with Hong Kong-based Pinehills (Hong Kong) Limited (**Pinehills**) for the supply of EZZ-branded products (the **Agreement**).

The five-year Agreement with Pinehills has commenced and involves the purchase of EZZ-branded products with a total value of at least A\$15 million in the first 12-month period with a growth escalator applied in each subsequent year as outlined in the summary terms below.

The Agreement with Pinehills provides EZZ with expanded distribution channels into the key markets of China and Vietnam as well as other markets within Southeast Asia.

Glenn Cross, Chairman of EZZ Life Science, commented: "We are delighted to announce this significant sales agreement with Pinehills. Pinehills has established a strong distribution platform into key markets where we see growing demand for EZZ's expanding range of products.

This agreement is a testament to our commitment to growth and innovation, and we are confident that it will enhance our market reach and customer base as we collaborate further with Pinehills over coming years."

Summary Terms of the Pinehills Agreement:

- Pinehills will purchase EZZ-branded products with a total value of at least A\$15 million in the first year, commencing May 2024.
- The annual purchase amount from Pinehills must increase by at least 10% each subsequent year (following the first year) until completion of the Agreement.
- Should Pinehills fail to meet the annual purchase growth requirements, EZZ has the right to claim all costs and losses from Pinehills.
- Agreement term is five years, concluding 30 April 2029.

About Pinehills

Established in 2022 and headquartered in the Hong Kong, Pinehills Limited specialises in the distribution of maternal and infant health, skincare and cosmetics products. Pinehills' management has extensive cross-border international trade experience and a comprehensive sales distribution network across China and a number of markets within Southeast Asia. Their strong presence on major online marketplaces and various online-to-offline (O2O) distribution channels positions the company as an important partner for EZZ in expanding its customer base.

This announcement has been authorised by the Board of EZZ Life Science Holdings Limited.

For further information, please contact:

Investor Relations

<https://www.ezzlife.com.au/investors>

ir@ezzlife.com.au

ENDS

About EZZ Life Science

EZZ Life Science Holding Limited (ASX:EZZ) is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on research and development in gene technology to address four key human health challenges: genetic longevity, human papillomavirus (HPV), children's health, and weight management. EZZ Life is passionate about investing in the future of consumer health through the development and distribution of high-quality health and wellness products including functional foods via expansive omnichannel models across Australia, New Zealand, China and worldwide. EZZ Life Science is led by an experienced senior management team that have implemented strategies to drive rapid and ongoing growth of the business.

For more information, please visit our corporate site ezzlife.com.au and our consumer site ezzdna.com.au.